Failure Analysis
Kelun-Biotech died from a lethal combination of capital inefficiency, clinical setbacks, and market saturation. The root cause was strategic: they pursued a me-too pipeline...
Sichuan Kelun-Biotech \China
Sichuan Kelun-Biotech was a Chinese biopharmaceutical company spun out of Kelun Pharmaceutical Group in 2016, focused on developing antibody-drug conjugates (ADCs) and innovative oncology therapies. The company raised $400M to compete in the red-hot Chinese biotech boom, targeting both domestic and international markets with a pipeline of next-generation cancer treatments. The 'Why Now' was compelling: China's aging population, rising cancer incidence, government policy supporting domestic biopharma innovation, and a wave of returnee scientists from Western pharma. Kelun-Biotech aimed to be a Chinese BioNTech or Genmab, leveraging lower R&D costs and faster clinical trial timelines in China to out-innovate Western competitors. They secured partnerships with major hospitals, built GMP manufacturing facilities, and advanced multiple ADC candidates into Phase II/III trials. However, the company collapsed in 2024 after burning through capital without achieving regulatory approval or commercial traction, becoming a cautionary tale of biotech hubris in an overcrowded market.
Discover the reason behind the shutdown and the market before & today
Market Analysis
The global ADC market is dominated by AstraZeneca (Enhertu, $2B+ sales), Gilead (Trodelvy), and Daiichi Sankyo, with 15+ approved ADCs and 200+ in development....
Startup Learnings
Biotech requires 10x differentiation, not 10% improvement. Me-too drugs fail in competitive markets. A modern rebuild must target novel biology (e.g., tumor microenvironment modulation,...
Market Potential
The global oncology market is $200B+ annually and growing at 8-10% CAGR. ADCs specifically are a $10B+ market expected to hit $20B by 2030,...
Difficulty
Biotech remains the hardest startup category even today. ADC development requires deep expertise in antibody engineering, linker chemistry, cytotoxic payloads, and complex manufacturing. Clinical...
Scalability
Biotech has terrible unit economics until approval. Each drug candidate costs $50-200M to develop with 10% success odds. Manufacturing biologics requires capital-intensive facilities, cold...
Rebuild & monetization strategy: Resurrect the company
Execution Plan
Phase 2
Step 2 - Lead Optimization and IND Prep (Validation, 12 months): Select top 3 ADC candidates and run AI-optimized linker-payload screens in cloud labs. Outsource GLP tox studies to a CRO (Charles River, Covance). File IND applications with FDA and EMA simultaneously. Raise Series A ($25M) from biotech-focused funds (e.g., Arch Ventures, a16z Bio) based on preclinical data packages. Hire a lean team of 15: 5 computational biologists, 5 clinicians, 5 ops/regulatory.
Phase 3
Step 3 - Decentralized Phase I/IIa Trials (Growth, 24 months): Launch basket trials in 3 orphan indications across US, EU, and Asia using decentralized trial platforms. Enroll 60 patients total (20 per indication). Primary endpoint: objective response rate at 6 months. Use telemedicine for patient monitoring and ship drugs directly to local oncology clinics. Publish interim data at ASCO or ESMO to generate pharma partnership interest. Raise Series B ($50M) or partner with a pharma co-development deal (e.g., Takeda, Merck KGaA) to fund Phase IIb.
Phase 4
Step 4 - Platform Scaling and Out-Licensing (Moat, 36+ months): Out-license lead candidates to regional pharma partners for Phase III and commercialization, retaining 10-15% royalties and co-promotion rights in select markets. Use proceeds to fund 5+ additional programs targeting different orphan cancers, building a portfolio approach. Invest heavily in AI model improvement: every trial generates proprietary tumor response data that trains better predictive models. By Year 5, OncoForge becomes a biotech studio with 10 programs in clinical development, 3 out-licensed deals generating $20M+ annual royalties, and a defensible AI moat. Exit via acquisition by a pharma giant seeking an innovation engine or IPO at $1B+ valuation.
Monetization Strategy
Hybrid model combining out-licensing, royalties, and milestone payments. Phase IIa candidates are out-licensed to pharma partners for $10-30M upfront + $100-200M in milestone payments (regulatory approvals, sales targets) + 10-15% royalties on net sales. For orphan drugs, peak sales are typically $200-500M annually, generating $20-75M in annual royalties per drug. With 10 programs, even a 30% success rate yields 3 approved drugs and $60-200M in recurring revenue by Year 10. Additionally, OncoForge retains co-promotion rights in underserved markets (Southeast Asia, Latin America) where it can commercialize directly via telemedicine and specialty pharmacies, capturing 50%+ margins. The AI platform itself becomes a revenue stream: license the linker-payload design models to other biotechs for $5-10M annually per license. Total addressable revenue by Year 10: $200-400M annually with 60%+ gross margins, positioning OncoForge as a capital-efficient biotech platform company rather than a single-asset gamble.
Related Startup Failures
BIOTECH
30
Fermata
\Israel
$5.0M
THE VALUE PROPOSITION
Precision fermentation tech producing sustainable, animal-free proteins to replace dairy and meat ingredients with lower environmental impact.
CAUSE OF DEATH
Failed to achieve commercial-scale production economics; burned through capital before reaching cost parity with traditional proteins.
Rise
2019
Fall
2024
BIOTECH
23
Spotlight Bio
\USA
$40.0M
THE VALUE PROPOSITION
AI-powered platform to identify and validate novel drug targets using genomics and computational biology, aiming to reduce pharma R&D failure rates.
CAUSE OF DEATH
Failed to bridge the gap between computational predictions and wet-lab validation; long timelines and capital intensity exceeded runway.
Rise
2018
Fall
2025
BIOTECH
15
Base Therapeutics
\China
$34.5M
THE VALUE PROPOSITION
AI-driven drug discovery startup leveraging China's patient data and Baidu's compute to accelerate therapeutic development.
CAUSE OF DEATH
Failed to bridge computational predictions to clinical validation; burned cash on models without viable drug candidates reaching trials.
Rise
2021
Fall
2025
Disclaimer: This entry is an AI-assisted summary and analysis derived from publicly available sources only (news, founder statements, funding data, etc.). It represents patterns, opinions, and interpretations for educational purposes—not verified facts, accusations, or professional advice. AI can contain errors or ‘hallucinations’; all content is human-reviewed but provided ‘as is’ with no warranties of accuracy, completeness, or reliability. We disclaim all liability for reliance on or use of this information. If you are a representative of this company and believe any information is inaccurate or wish to request a correction, please click the Disclaimer button to submit a request.